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Abstract
Purpose—To compare three year outcomes and complications of the Ahmed FP7 Glaucoma
Valve (AGV) and Baerveldt 101–350 Glaucoma Implant (BGI) for the treatment of refractory
glaucoma.
Design—Multicenter randomized controlled clinical trial.
Participants—276 patients; 143 in the AGV group and 133 in the BGI group.
Methods—Patients aged 18–85 years with refractory glaucoma and intraocular pressures (IOPs)
≥18 mmHg in whom an aqueous shunt was planned were randomized to either an AGV or a BGI.
Main Outcome Measures—IOP, visual acuity, supplemental medical therapy, complications,
and failure (IOP > 21 mmHg or not reduced by 20% from baseline, IOP ≤ 5 mmHg, reoperation
for glaucoma or removal of implant, or loss of light perception vision).
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Results—At 3 years, IOP (mean ± standard deviation) (SD) was 14.3 ± 4.7 mmHg (AGV group)
and 13.1 ± 4.5 mmHg (BGI group) (p = 0.086) on 2.0 ± 1.4 and 1.5 ± 1.4 glaucoma medications
respectively (p = 0.020). The cumulative probabilities of failure were 31.3% (standard error =
4.0%) (SE) (AGV) and 32.3% (4.2%) (BGI) (p = 0.99). Postoperative complications associated
with reoperation or vision loss of ≥ 2 Snellen lines occurred in 24 patients (22%) (AGV) and 38
patients (36%) (BGI) (p = 0.035). The mean change in the Logarithm of the Minimum Angle of
Resolution visual acuity (logMAR VA) at 3 years was similar (AGV: 0.21 ± 0.88, BGI: 0.26 ±
0.74) in the two treatment groups at 3 years (p=0.66). The cumulative proportion of patients (SE)
undergoing reoperation for glaucoma prior to the three year postoperative time point was 14.5%
(3.0%) in the AGV group compared to 7.6% (2.4%) in the BGI group (p=0.053, log-rank). The
relative risk of reoperation for glaucoma in the AGV group was 2.1 times that of the BGI group
(95% Confidence Interval:1.0–4.8, p=0.045; Cox proportional hazards regression).
Conclusions—AGV implantation was associated with the need for significantly greater
adjunctive medication to achieve equal success relative to BGI implantation and resulted in a
greater relative risk of reoperation for glaucoma. More subjects experienced serious postoperative
complications in the BGI group than in the AGV group.
Aqueous shunts are used increasingly in the management of glaucoma in situations where
trabeculectomy is unlikely to succeed or has failed. Published data from the United States
Medicare database for glaucoma procedures performed between 1995 and 2004 demonstrate
a 184% increase in the number of aqueous shunt procedures.1 This trend has continued with
a further increase from 7754 shunts in 2004 to 11311 in 2010 (Personal communication,
Anne L Coleman – American Academy of Ophthalmology H Dunbar Hoskins Center for
Quality Care). The 5 year results of the Tube versus Trabeculectomy Study, which showed a
higher success rate with the use of the Baerveldt glaucoma implant (BGI, Abbott Medical
Optics, Abbott Park, IL) than with trabeculectomy with adjunctive mitomycin C in patients
with prior failed filtration surgery and/or cataract surgery, has stimulated interest in aqueous
shunt implantation in similar patient groups.2;3
The Ahmed glaucoma valve (AGV, New World Medical, Cucamonga, CA) and BGI are two
of the shunts most commonly used in clinical practice, sharing a common design of a tube
that shunts aqueous humor from the anterior chamber to an endplate located at the equatorial
region of the globe. Aqueous shunts differ in terms of materials and design features,
including the presence or absence of a flow restrictor designed to limit aqueous flow and
hence reduce the risk of postoperative low intraocular pressure (IOP). Surgeons choose
specific aqueous shunts for various reasons, including perceived efficacy in controlling IOP,
perceived risks of complications, and ease of implantation.
There have been several retrospective studies reporting the relative rates of complications
and successful IOP control when these implants have been used in refractory glaucomas. 4–8
The purported advantage of AGV implantation is early postoperative IOP control and
reduced risk of hypotony due to a flow restrictor. Although the BGI has no flow restrictor,
some believe that certain features of its plate design reduce the tendency to encapsulate.
These include its large surface area, low, curved profile, and polished surface.9,10 In
addition, it has been postulated that complete occlusion of non-valved implants such as the
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BGI for the first four to six weeks postoperatively limits inflammatory mediators from
entering the bleb with the consequent reduction in the likelihood of bleb encapsulation.11
Success rates reported for the AGV range from 68 to 100% and for the BGI from 43 – 100%
with such rates being highly dependent upon the length of follow-up, type of glaucoma, and
success criteria.12 A recent Ophthalmic Technology Assessment report by the American
Academy of Ophthalmology states that “Too few high-quality direct comparisons of various
available shunts have been published to assess the relative efficacy or complication rates of
specific devices…”,13 highlighting the need for randomized clinical trials in this area.
Currently two randomized clinical trials have been designed to compare prospectively these
two commonly used implants: the Ahmed versus Baerveldt (AVB) Study14 and the Ahmed
Baerveldt Comparison (ABC) Study.15 The Ahmed Baerveldt Comparison (ABC) Study
was designed to compare prospectively the safety and efficacy of AGV model FP7 and BGI
model 101–350 implantation for refractory glaucoma. Patients with uncontrolled glaucoma
who had prior incisional surgery or other glaucoma diagnoses known to be poor candidates
for trabeculectomy were enrolled in this multicenter clinical trial and randomized to
placement of one of these two implants. The ABC Study has previously reported a
comparison of these two implants with one year postoperative follow up.16 In this
manuscript we report the treatment outcomes of the ABC Study after three years of follow-
up.
METHODS
The Institutional Review Board at each of 16 Clinical Centers approved the study protocol
before recruitment was started, and each patient gave informed consent. The study was
registered at www.clinicaltrials.gov (accessed November 24th 2013). The design and
methods of the ABC Study are described in detail in a baseline methodology paper,15 and
are summarized as follows.
Randomization and Treatment
Eligibility was independently confirmed at the Statistical Coordinating Center (SCC) at the
Bascom Palmer Eye Institute. Individuals enrolled in the study were randomized to
placement of an AGV FP7 or BGI 101–350 according to a permuted variable block
randomization scheme, stratified by surgeon within Clinical Center and type of glaucoma.
Patients aged 18–85 years with refractory glaucoma and intraocular pressures (IOPs) greater
than or equal to 18 mmHg in whom an aqueous shunt was planned were randomized to
undergo implantation of either an AGV or a BGI. Patients with primary glaucomas with a
previous failed trabeculectomy or other intraocular surgery were included. Also, patients
without previous intraocular surgery were eligible if they had secondary glaucomas known
to have a high failure rate with trabeculectomy such as neovascular, uveitic, or iridocorneal
endothelialization syndrome-associated glaucoma.
Enrolled patients were allocated to one of 4 strata according to their type of glaucoma, as
follows: (1) Primary glaucomas with previous intraocular surgery; (2) Secondary glaucomas
(excluding uveitic and neovascular glaucomas (NVG)); (3) NVG; (4) Uveitic glaucoma.
Neither the subject nor investigator was masked to the randomization assignment. Details of
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the surgical procedures for AGV and BGI implantation used in this study are described in
the baseline paper.15
Patient Visits
Follow-up visits were scheduled one day, one week, one month, three months, six months,
one year, 18 months, two years, three years, four years, and five years postoperatively.
Information about data obtained at baseline and follow-up visits is contained in the baseline
paper.15
Primary and Secondary Outcome Measures
The outcome measures used in the ABC Study were largely surrogates for patient functional
outcomes that were not measured in the study. The primary outcome measure was failure,
which was defined prospectively as IOP > 21 mmHg or less than a 20% reduction below
baseline on 2 consecutive study visits after three months, IOP ≤ 5 mmHg on 2 consecutive
study visits after three months, reoperation for glaucoma, loss of light perception vision, or
removal of the implant for any reason. Reoperation for glaucoma was defined as additional
glaucoma surgery requiring a return to the operating room (cyclodestruction was counted as
a reoperation for glaucoma whether or not the procedure was performed in the operating
room). Interventions performed at the slit lamp, such as needling procedures, removal of
occluding stents, or laser suture lysis, were not considered glaucoma reoperations.
IOP and the rate of surgical complications were secondary outcome measures in the ABC
Study. Early complications were those that were recorded by the three-month follow-up visit
whereas late complications were those that were experienced after the three-month follow-
up visit. A serious complication was defined as any complication, early or late, that was
associated with a two line Snellen acuity decrease and/or a return to the operating room for a
surgical procedure to manage the complication.
A revision in the operating room to manage an occluded tube was considered a reoperation
for a complication. The Snellen visual acuity decrease was assessed at the three-year visit. If
the patient did not have a three-year visit, then their complication could not be categorized
as serious by vision loss, but could by virtue of reoperation.
Change in definition
The current manuscript includes a change in the definition of a loss of “two Snellen lines”
for those with visual acuities below counting fingers (CF). In the one year treatment
outcomes manuscript,17 a decrease in acuity from CF to hand motions (HM) and from HM
to light perception (LP) was considered as “two Snellen lines” of change. To reflect
differing investigators’ views on this matter, such a decrease is considered a “one-line”
reduction in acuity in this manuscript. CF to HM is therefore considered to be a "one line"
reduction in acuity.
Statistical Analysis
Snellen VA measurements were converted to Logarithm of the Minium Angle of Resolution
visual acuity (logMAR VA) equivalents for the purpose of data analysis, as reported
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previously.15;18 The time to failure was defined either as the time from surgical treatment to
reoperation for glaucoma, loss of acuity to no light perception (NLP) in the study eye, or as
the time from surgical treatment to the first of two consecutive follow-up visits after three
months in which the patient had persistent hypotony (IOP ≤ 5 mmHg) or inadequately
controlled IOP (IOP > 21 mmHg or not reduced by 20%). Data on IOP and numbers of
glaucoma medications were censored once a subject underwent a reoperation for glaucoma,
explantation of the implant for a complication, or loss of light perception vision, but not
after failure due to high IOP, hypotony, or reoperation for a complication. There was no
censoring of visual acuity results. Univariate comparisons between treatment groups were
performed with the two-sided Student t-test for continuous variables and the chi-square test
or Fisher’s exact test for categorical variables. Risk factors for treatment failure were
assessed for statistical significance with the Kaplan-Meier survival analysis log-rank test.
Multivariate analysis was performed with Cox proportional hazard regression analysis with
forward stepwise elimination. Patients’ data were analyzed in the group to which they were




A total of 276 patients were enrolled between October 2006 and April 2008. 143 patients
(52%) were randomly assigned to placement of an AGV and 133 (48%) to a BGI. Protocol
violations are described in the baseline paper.15 All patients were analyzed in the group to
which they were originally assigned according to the intent-to-treat protocol.
Retention of patients in the study at three years is illustrated in Figure 1. In the overall study
group, 223 (81%) patients attended at least three years of follow-up. This included 113
(79%) patients in the AGV group and 110 (83%) in the BGI group. 106 (74%) AGV patients
completed the actual three-year visit compared to 100 (75%) BGI patients. The number of
patients completing each follow-up visit is shown in Table 1.
We compared patients who returned for three year visits (n=144) to those who did not
(n=39), excluding from analysis those who had died prior to the end of the 3 year visit
window (n=10) and those who had previously been classified as failing pressure control
(n=83). Participants not returning for 3 year visits were more likely to have neovascular
glaucoma (p<0.001); be of Hispanic ethnicity (p<0.044); have higher intraocular pressures
at baseline (p=0.048) and year 2 (p=0.022) but not year 1 (p=0.30) of follow up; and have
worse visual acuity at baseline (p=0.069), year 1 (p=0.032), and year 2 (p<0.034). However
patients failing to return for 3 year follow up were not different with respect to gender
(p=0.37), age (p=0.18), ethnicity (p=0.26), or randomized treatment group (p=1.00). Thus,
whatever selection biases lead to differential follow up, they should not affect the
randomized treatment comparison.
Barton et al. Page 5























There were no differences in baseline demographic or clinical characteristics between the
two groups as detailed in the baseline paper.15
IOP Reduction
The baseline and follow-up IOPs for the two groups are reported in Table 1 and Figure 2.
Patients who underwent additional glaucoma surgery were censored from analysis after the
time of reoperation, as were those undergoing explantation for any reason and those who
lost light perception in the study eye. Both study groups experienced a significant reduction
in IOP. In the AGV group, IOP (mean ± standard deviation; SD) reduced from 31.2 ± 11.2
mmHg at baseline to 14.3 ± 4.7 mmHg at the three-year follow-up visit (p < 0.001, paired t-
test). In the BGI group, IOP (mean ± SD) was reduced from 31.8 ± 12.5 mmHg at baseline
to 13.1 ± 4.5 mmHg at the three-year follow-up visit (p < 0.001, paired t-test). The IOP
difference between the two treatment arms at three years was not statistically significant
(p=0.086). The AGV group had a significantly lower mean IOP than the BGI group at the
one day and one week follow-up visits, the mean IOP in the BGI group was approximately 1
to 2 mmHg lower than the AGV group thereafter except at the two-year visit.
Medical Therapy
Table 1 also shows the number of glaucoma medications in both groups at baseline and
follow-up. Patients who underwent additional glaucoma surgery were censored from
analysis after the time of reoperation. There was a significant reduction in the need for
medical therapy in both treatment groups (Figure 3). The number of glaucoma medications
(mean ± SD) in the AGV group decreased from 3.4 ± 1.1 at baseline to 2.0 ± 1.4 at the
three-year follow-up visit (p < 0.001, paired t-test). The number of glaucoma medications
(mean ± SD) in the BGI group was reduced from 3.5 ± 1.1 at baseline to 1.5 ± 1.4 at the
three-year follow-up visit (p < 0.001, paired t-test). Subjects in the AGV group were using
significantly more mediations at both two and three years as compared to the BGI group (p
= 0.020 for each).
Treatment Outcomes
Table 2 compares the outcomes and reasons for failure of randomized patients, unadjusted
for follow-up time. All patients who were seen at the three-year follow-up visit and/or failed
during the first three years of the study were included in this analysis. While the total
numbers of failures were similar in the two groups, the number failing due to uncontrolled
high IOP or reoperation for glaucoma was 34 in the AGV group (representing 79% of AGV
failures) compared to 22 in the BGI group (55% of BGI failures), a statistically significant
difference (p=0.034). An alternative statement of this result is that only 9 AGV eyes (21% of
AGV failures) experienced persistent hypotony, complications for which explantation was
performed, or losing light perception in the study eye compared to 18 (45% of failures) in
the BGI group.
Kaplan-Meier survival analysis was used to compare failure rates between the two treatment
groups (Figure 4). The cumulative probability of failure (standard error) (SE) was 31.3%
(4.0%) in the AGV group and 32.3% (4.2%) in the BGI group at three years (p=0.99, log-
Barton et al. Page 6






















rank test). The relative risk of treatment failure in the AGV group was 1.0 times that in the
BGI group (95% Confidence Interval (CI): 0.7–1.6, p=0.99 Cox proportional hazards
regression). There was no suggestion of different treatment effects in the four randomized
strata (p = 0.72, three degree of freedom test of treatment group by stratum interaction).
The cumulative proportion of patients (SE) undergoing reoperation for glaucoma prior to the
three year postoperative timepoint was 14.5% (3.0%) in the AGV group compared to 7.6%
(2.4%) in the BGI group (p=0.053, log-rank test; figure 4). The relative risk of reoperation
for glaucoma in the AGV group was 2.1 times that of the BGI group (95% CI:1.0–4.8,
p=0.045; Cox proportional hazards regression).
The failure rates for the two treatment groups were examined with alternative outcome
criteria. Patients with persistent hypotony, reoperation for glaucoma, or loss of light
perception vision were still classified as treatment failures; however, the upper IOP limit
defining success and failure was changed. When inadequate IOP control was defined as IOP
greater than 17 mmHg or not reduced by 20% on two consecutive follow-up visits after
three months, the cumulative probability of failure at three years was 44.3% (4.3%) in the
AGV group and 36.9% (4.3%) in the BGI group (p = .17, stratified log rank test). When
inadequate IOP control was defined as IOP greater than 14 mmHg or not reduced by 20% on
two consecutive follow-up visits after three months, the cumulative probability of failure
was 67.2% (4.0%) in the AGV group and 52.6% in the BGI group at three years (p = .003,
stratified log rank test).
Patients with a three-year follow up visit who were still successful through that visit were
divided into complete and qualified success based on the requirement for IOP-lowering
medical therapy at three years. The number (%) of complete successes at three years was 15
(20%) in the AGV group compared to 23 (33%) in the BGI group (p=0.093, Fisher exact
test).
Because the surgeon was not masked to the treatment assignment, a potential bias existed in
the decision to reoperate for IOP control. To evaluate for reoperation bias, the IOP levels
were compared between treatment groups among patients who failed because of inadequate
IOP control. For cases failing by high IOP at two consecutive study visits (e.g. 6 and 12
months or 18 and 24 months) without reoperation, the average of the failing IOPs was
calculated and compared between the two randomized groups. The average (SD) failing IOP
in the AGV group was 21.5 mmHg (6.3) compared to 23.2 (8.4) in the BGI group (p=0.51,
two-sample t-test). Among AGV cases reoperated for glaucoma the mean (SD) preoperative
IOP immediately prior to reoperation was 32.4 (10.8) compared to 24.9 (5.6) in the BGI
group (p=0.094). Although not statistically significant, this latter difference suggests a
possibly higher, rather than lower, threshold for reoperation in the AGV, compared to the
BGI, group.
Visual Acuity
Visual acuity results are shown in Table 3. There was a significant decrease in Snellen VA
in both treatment groups during the first three years of follow-up. In the AGV group,
logMAR Snellen VA (mean ± SD) decreased from 1.07 ± 1.01 at baseline to 1.16 ± 1.07 at
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the three-year follow-up visit (p = 0.019, paired t-test). In the BGI group, logMAR Snellen
VA (mean ± SD) decreased from 1.04 ± 1.00 at baseline to 1.19 ± 1.28 at the three-year
follow-up visit (p = .001, paired t-test). There was no significant difference in logMAR
Snellen VA (p = 0.75, student t-test) between the two groups at three years.
Snellen VA was decreased by two or more lines from baseline in 36 (35%) patients in the
AGV group and 30 (30%) patients in the BGI group at three years, and this difference in rate
of vision loss between treatment groups was not statistically significant (p = 0.46, Fisher’s
exact test). The most frequent causes of vision loss during three years of follow-up were
glaucoma, retinal disease, and cataract. The reason for decreased vision was unknown in 4
(11%) patients in the AGV group and 1 (3%) patients in the BGI group. Other miscellaneous
causes for reduced vision in eight patients in the AGV group included vitreous hemorrhage,
corneal epithelial defect, retinal detachment, diabetic retinopathy, band keratopathy, and
neovascular membrane. Other causes of vision loss in 11 patients in the BGI group included
corneal edema, retinal detachment, diabetic retinopathy, endophthalmitis, and posterior
capsular opacification. There were no significant differences in the reasons for visual acuity
loss between the two groups.
Postoperative Interventions
The most frequently performed postoperative intervention between the 18 month and three
year postoperative time points was cataract extraction. The total number of interventions
was 15 in the AGV group and 17 in the BGI group, a difference which was not statistically
significant (p=0.50, Chi-squared test).
Postoperative Complications
Table 4 shows the cumulative proportions of late complications at three years in each
treatment group. Fifty five patients (44.7%) in the AGV group developed a late
complication, compared with 63 (61.5%) in the BGI group (p=0.13, log rank). The rate of
phthisis bulbi was significantly higher in the BGI group (0 vs 5 (or 3.6%), p=0.023 log
rank). At three years there was also a significant difference in tube occlusion between the
two groups, with 1 (0.8%) in the AGV group, and 6 (4.9%) in the BGI group (p = 0.039 log
rank). Fourteen eyes (12.4%) in the AGV group had corneal edema at 3 years compared
with 15 (15.7%) BGI eyes (p=0.51). In order to determine the likelihood of corneal edema
related to the aqueous shunt, one investigator (DLB) re-examined all of the data collection
forms retrospectively masked to treatment assignment and early postoperative visits to
exclude patients with corneal edema related to pre-existing corneal disease. As a result, we
concluded that seven (6.4%) of AGV and nine (10.1%) of BGI had corneal edema (p=0.42
log rank) that was not attributable to underlying corneal disease. These figures exclude
patients who had early postoperative corneal edema that subsequently resolved.
The number of patients experiencing serious complications, defined a priori as
complications that required a return to the operating room to manage the complication
and/or associated with loss of two or more lines of Snellen visual acuity, was significantly
higher in the BGI group (n = 38, 36%) than in the AGV group (n = 24, 20%, p = 0.035).
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Table 5 shows complications by NVG versus other strata. Table 6 provides complete data
for serious complications.
Reoperation for Complications
Reoperations for complications (Table 6), including explantations, were performed in 12
(11%) patients in the AGV group and 21 (20%) patients in the BGI group. At year three, the
cumulative proportion (SE) of complication-related reoperations in the AGV group was
9.2% (2.5%) compared to 16.6% (3.3%) in the BGI group (p=0.060, log-rank test). In the
AGV group, reasons for complication-related reoperations included: revise exposed tube (1),
reposition the tube (1), place tube extender (2), new patch graft (1), and removal of
occlusions (3), repair wound leak (1). In addition there were three explantations in the AGV
group, two for diplopia and one for extrusion. In the BGI group, the reasons for reoperation
for complications included: removal of occlusions (7), repair patch graft (1), repair tube
erosion (2), repair bleb leak (1), reposition tube (1), ligate tube for over-filtration (1), and
drain suprachoroidal hemorrhage (1), pars plana vitrectomy (2) and penetrating keratoplasty
(1). In addition there were four explantations, one for chronic endophthalmitis, one for
corneal touch, one for exposure and one for chronic pain.
Cataract Surgery during Follow-Up
There were 92 phakic patients in the study, 47 in the AGV group and 45 in the BGI group.
The cumulative proportion (SE) undergoing cataract extraction in the AGV group was
40.6% (8.3%) compared to 40.1% (7.9%) in the BGI group (p=0.79, log rank test).
DISCUSSION
The primary outcome measure of the ABC Study was failure to control IOP, defined
prospectively as IOP > 21 mmHg or less than a 20% reduction below baseline on 2
consecutive study visits after three months, IOP ≤ 5 mmHg on 2 consecutive study visits
after three months, reoperation for glaucoma, loss of light perception vision, or removal of
the implant for any reason. There was no statistically significant difference between the two
implant groups with regard to the primary outcome measure. Both procedures lowered IOP
and medication use significantly at three years from baseline. The AGV group had a higher
rate of reoperation for glaucoma than the BGI group (Table 2) but this was of borderline
significance (p=0.054). The mean IOP was 1.2 mmHg lower at three years with the BGI.
Although this difference was not statistically significant (p=0.086) it is noteworthy the BGI
group was also receiving fewer postoperative IOP lowering medications at the three year
time point, a difference which was statistically significant.(p=0.020).
Seventy nine percent of AGV failures occurred as a result of high IOP or reoperation for
high IOP (Table 2), whereas 46% of BGI failures were due to low IOP or surgery-related
complications. We checked for a systematic difference in the threshold for reoperation for
high IOP and found that the higher threshold for reoperation in the AGV group than the BGI
group was not statistically significant. If such a bias existed, it favored the AGV.
When an alternative outcome based on an upper limit for IOP ≥14 mmHg or < 20%
reduction from baseline was tested, 19 the BGI was significantly more successful than the
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AGV in meeting this lower IOP target (p =.003). However, in this study neither device had
notable success at achieving such low IOP levels: the AGV failed in 67.2% and the BGI
failed in 52.6%. These high levels of failure are no doubt explained by the high risk case
mix recruited for the ABC Study. In the TVT Study (where the BGI was the only implant
used, and where the case mix was lower risk), low IOP’s, comparable to trabeculectomy,
were commonly achieved with the BGI. SSSS20 In comparison with the TVT Study, it is
interesting to note that although the IOP at baseline was higher in the ABC BGI group (31.8
± 12.5mmHg) than the TVT BGI group (25.1 ± 5.3 mmHg), the IOP levels at 3 years were
very similar in the two studies at 13.0 ± 4.9 mmHg on 1.3 ± 1.3 glaucoma medications in the
TVT BGI group and 13.1 ± 4.5 mmHg on 1.5 ± 1.4 glaucoma medications in the ABC BGI
group. With similar failure definitions in the two studies, 15% failed at 3 years in the TVT
BGI group, with 54% qualified successes and 31% complete successes. In the ABC BGI
group, the equivalent figures were 40% failing at 3 years, 27% qualified successes and 33%
complete successes.
Figure 5 suggests that Ahmed valves required reoperations at a rate of about 8% per year
beginning in the early post-perioperative period. Baerveldt implants appeared to fail at a
similar rate, but with onset delayed until about 18 months following implantation. The
planned 5 year data analysis may indicate whether the Kaplan-Meier reoperation curves
converge in late follow up.
The number of serious complications at three years was similar in the two groups, except for
5 cases of phthisis bulbi in the BGI group compared with none in the AGV group (p=0.023
log rank) (Table 4). Table 5 illustrates a breakdown of complications between the
neovascular glaucoma (NVG) stratum and other strata, and it can be seen that a number of
complications, including corneal edema, phthisis bulbi, hyphema and vitreous hemorrhage
were statistically significantly more common in the NVG stratum. Specifically, 4 out of 5
eyes developing phthisis bulbi by three years were in the NVG stratum. Although NVG eyes
perform less well, we did not observe a difference in treatment efficacy between the two
treatment groups in this stratum. We did not specifically attempt to decide whether
complications were attributable to the aqueous shunt as opposed to underlying diagnosis
except in the case of corneal edema, as described above.
It is worth noting that in the one year treatment outcome manuscript, a reduction in VA from
CF to HM, or HM to LP, was considered a two line loss, whereas in the three-year analysis
we have recorded these changes as a one line loss. The mean logMAR visual acuity had
decreased in both treatment groups during the first year of follow-up,15 but improved
slightly in each by three years (Table 3). The proportion of subjects losing 2 or more lines of
Snellen acuity was similar at one year (30% of AGV and 34% of BGI) and three years (35%
of AGV and 30% of BGI). Most of the causes of loss of two or more Snellen lines were
related to cataract, retinal disease and glaucoma and were not directly attributable to the
surgical procedures under study (Table 3).
In comparison with the BGI arm of the TVT Study, complications were reported in a higher
proportion of ABC Study patients at 3 years (51.5% in the BGI group and 44.7% in the
AGV group), than in the former (39%). This is not unexpected given that many patients
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enrolled in the ABC Study suffered from conditions with a poorer visual prognosis and
higher tendency to complications, than in the TVT study.
Tube occlusion and phthisis bulbi, which were substantially more common in the ABC BGI
group were reported in 3% (tube occlusions) of the BGI group in the TVT study and 0%
(phthisis bulbi) in the TVT study. The tube occlusion rate in the TVT study was therefore
closer to that of the BGI than AGV group in the ABC study. The reporting of no cases of
phthisis bulbi in the TVT Study is in keeping with the observation that 4 out of 5 cases in the
ABC BGI group suffered from neovascular glaucoma, an exclusion criterion for the TVT
study.
Interestingly many complications commonly associated with tubes (dipopia, corneal edema
and erosion) were similar but slightly lower in the ABC than TVT Study. Diplopia was
reported in 5% of TVT Baerveldts compared with 2.8% in each arm of ABC. Corneal edema
was observed in 9% of TVT tubes, but 3.9% of ABC BGI and 3.1% of ABC AGV. Erosion
was observed in 5% of TVT Baerveldts compared with 0.9% ABC BGI and 1.1% of ABC
AGV.
In summary, the ABC Study observed a 54% reduction in IOP in enrolled eyes at three
years, with a similar rate of treatment failure in the two treatment groups, though most AGV
failures (79%) were for high IOP, while most BGI failures (55%) were for low IOP or
complications. The BGI group had slightly lower IOPs at three years on significantly fewer
ocular hypotensive medications. While the rate of complications was not significantly
different between the two groups, the BGI group were more likely to be reoperated for a
complication or suffer 2 or more lines of Snellen vision loss. The rates of a number of
serious complications were higher in the NVG stratum than other strata, though we observed
no difference in the treatment efficacy between study groups within the NVG stratum.
The ABC Study has much in common with the Ahmed versus Baerveldt (AVB) Study, a
randomized surgical trial comparing the same two implants.14;16 The AVB Study
randomized 238 patients (124 to the AGV and 114 to the BGI) with similar but slightly
broader patient eligibility to the ABC Study. There were minor demographic differences
with a slight female preponderance in the BGI group and more white patients in the AVB
Study, with slightly more POAG (50% versus 40%) and less NVG (21% versus 29%)
compared with ABC. The AVB Study differed from ABC in that all surgeons were
experienced users of both types of implants and that treatment allocation was decided by a
coin toss. In their primary outcome measure, the AVB Study investigators used a more
stringent cut-off of >18 mmHg for high pressure failure and a slightly less stringent limit of
<5 mmHg for hypotony (cf. > 21 mmHg and <6 mmHg in the ABC Study) and additionally
included sight-threatening complications in its definition of failure.
At present, it is possible to compare treatment outcomes at one year between the two studies.
Retention was similar in both. The reported cumulative probability of failure was higher
with the AGV in both studies but only significantly higher in AVB (AVB: p=0.049, ABC: p
= 0.52). AGV IOPs were higher than BGI in both studies (both p<0.01) and the AGV group
averaged 0.4 (AVB, p=0.03) and 0.3 (ABC, p=0.07) more medications than the BGI group.
Barton et al. Page 11






















The reported failure rate of 43% in the AGV group compared with 28% in the BGI group in
the AVB Study are higher than the corresponding failure rates of 16% and 14% respectively
in the ABC Study. Potential explanations for this could include the more stringent upper IOP
limit and inclusion of sight-threatening complications in the definition of failure in the AVB
study. However, when the two studies are compared with the alternative IOP end-point of
≥18 mmHg that was also reported by the ABC Study group, and which is close to the
definition of >18 mmHg used by the AVB Study, and when sight-threatening complications
are removed from the definition of failure in the AVB Study, the corresponding failure rates
for the BGI are 24% (AVB) and 16% (ABC), and for the AGV remain at 41% (AVB) and
22% (ABC).
In contrast to the ABC Study that reported more complications in the BGI than AGV group,
no significant difference in overall number of complications between the two groups was
observed in the AVB Study, though significantly more patients required reintervention in the
BGI group. A comparison of individual complications reveals some similarities between the
two studies: 10% more corneal edema in the BGI group than in the AGV group (both studies
p<0.05) and more tube obstruction in BGI group (AVB 6%, p=0.12 and ABC 7%, p=0.02)
than in the AGV group. The AVB Study reported an 8% higher rate of encapsulated blebs in
the AGV group than in the BGI group (p=0.01).
Motility disturbances with the AGV were similar to the ABC Study at 6% in the AGV group
in both studies. The rate of motility disturbance listed in the AVB Study with the BGI was
3% at one year, compared with 5% reporting diplopia in the ABC Study. It is interesting to
note that the prevalence of dioplopia at three years in the ABC Study appeared to diminish
as compared to one year (2.8% in each treatment arm). Once a motility disturbance appeared
it was included in the cumulative incidence rate (table 4); however the cross sectional rate at
3 years was lower than at one year. This was due both to removal of the implants,
complications were censored after removal of the study implant and such cases would not be
included in either the numerator or denominator of the cross-sectional 3 year rate, but also
because of spontaneous resolution of symptoms when that occurred, which it did in some
patients.
In the longer term the combined data of these two similar studies should provide a valuable
insight into the relative benefits and drawbacks of these two implants. Currently, the three
year treatment outcomes of the ABC Study do not demonstrate clear superiority of one
implant over the other, although the trend towards greater efficacy in the BGI group with
fewer complications in the AGV group that was observed at one year is still present at three
years. The ABC Study is designed to continue follow-up of participants out to five years.
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Figure 1. Study Flow Diagram
Recruitument and retention in the ABC study at three years.
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Figure 2. Intraocular Pressure (IOP) by randomized treatment group and follow-up visit
Graph of IOP (mmHg) in the Ahmed Baerveldt Comparison (ABC) Study by study group
from preoperative level to last follow-up (mean ± standard deviation (SD))
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Figure 3. Medication use by randomized treatment group and follow-up visit
Histogram of the number of classes of ocular hypotensive medication used from before
surgery to three year follow-up visit (mean ± standard deviation (SD))
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Figure 4. Kaplan-Meier cumulative surgical failure rates by randomized treatment group
Kaplan-Meier survival curve of cumulative surgical failures over three years of follow-up by
treatment group.
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Figure 5. Kaplan-Meier cumulative reoperation rates by randomized treatment group
Kaplan-Meier survival curve of cumulative reoperation rates by randomized treatment group
in the first three years of follow-up.
Barton et al. Page 20











































Barton et al. Page 21
Table 1
Intraocular Pressure and Medical Therapy at Baseline and Follow-up in the Ahmed Baerveldt Comparison
Study*
Ahmed Group Baerveldt Group P-value†
Baseline
  IOP (mm Hg) 31.2 ± 11.2 31.8 ± 12.5 .71
  Glaucoma medications 3.4 ± 1.1 3.5 ± 1.1 .34
  N 143 133
1 month
  IOP (mm Hg) 20.7 ± 9.7 18.0 ± 10.0 0 .026
  Glaucoma medications 0.5 ± 1.1 1.3 ± 1.5 < 0.001
  N followed (% of baseline) 141 (99%) 131 (98%)
3 months
  IOP (mm Hg) 18.8 ± 8.2 16.7 ± 8.2 0.044
  Glaucoma medications 1.4 ± 1.3 1.2 ± 1.3 0.28
  N followed (% of baseline) 134 (94%) 125 (94%)
6 months
  IOP (mm Hg) 15.7 ± 5.3 14.8 ± 6.8 0.27
  Glaucoma medications 1.7 ± 1.4 1.3 ± 1.3 0.010
  N followed (% of baseline) 131 (92%) 125 (94%)
1 year
  IOP (mm Hg) 15.4 ± 5.5 13.4 ± 6.9 0.018
  Glaucoma medications 1.8 ± 1.3 1.5 ± 1.4 0.078
  N followed (% of baseline) 133 (93%) 117(88%)
18 months
  IOP (mm Hg) 14.8 ± 4.6 13.3 ± 4.6 0.034
  Glaucoma medications 1.8 ± 1.4 1.4 ± 1.4 0.068
  N followed (% of baseline) 121 (85%) 106 (80%)
2 years
  IOP (mm Hg) 14.5 ± 5.5 14.2 ± 6.0 0.76
  Glaucoma medications 1.9 ± 1.3 1.4 ± 1.5 0.020
  N followed (% of baseline) 122 (85%) 110 (83%)
3 years
  IOP (mm Hg) 14.3 ± 4.7 13.1 ± 4.5 0.086
  Glaucoma medications 2.0 ± 1.4 1.5 ± 1.4 0.020
  N followed (% of baseline) 106 (74%) 100 (75%)
Data are presented as mean ± standard deviation (SD).
IOP = intraocular pressure
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Table 2
Reasons for Treatment Failure in the Ahmed Baerveldt Comparison Study were different by treatment group
Ahmed Group Baerveldt Group
Inadequate IOP control without additional glaucoma surgery 18 (42) 15 (38)
Reoperation to lower IOP 16 (37) 7 (18)
Explantation for complication 3 (7) 4 (10)
Persistent hypotony* 1 (2) 5 (13)
Loss of light perception 5 (12) 9 (23)
Total 43 40
Data are presented as number (percentage of the total number of failures in each respective treatment allocation group). P = 0.109 (Fisher exact).
There were significantly more failures for IOP elevation and reoperation to lower IOP than other causes of failure (p=0.034)
IOP = intraocular pressure
*
IOP ≤ 5 mm Hg at 2 consecutive visits after 3 months
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Table 3






Snellen VA, logMAR mean ± SD
  Baseline (n=276) 1.07 ± 1.01 1.04 ± 1.00 .80†
  3 years (n=205) 1.16 ± 1.07 1.19 ± 1.28 0.83†
  Change at 3 years (n=205) 0.21 ± 0.88 0.26 ± 0.74 .66†
Loss of ≥ 2 Snellen lines at 3 years, n (%)* 36 (35%) 30 (30%) 0.55‡
  Glaucoma 14 (39%) 9 (30%)
  Retinal disease 8 (22%) 5 (17%)
  Cataract 3 (8%) 4 (13%)
  Other 8 (22%) 11 (37%)
  Unknown 4 (11%) 1 (3%)
*
Patients may have more than one reason for decreased vision. In the one year manuscript, a change in acuity from counting fingers (CF) to hand
motions (HM) and a change from HM to light perception (LP) was considered a two Snellen line loss. In the current manuscript these are
considered a one Snellen line loss.
†
Two sided Student t-test
‡
Fisher exact test
VA = Visual Acuity, Logmar = Logarithm of the Minium Angle of Resolution visual acuity, SD = Standard Deviation
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Table 5
Complications by Neovascular Glaucoma (NVG) versus other strata (1, 2, 4).
Complication




Tube occlusion 3 5.5% (3.2%) 4, 2.3% (1.1%) 0.31
Choroidal effusion 1 1.8% (1.7%) 1, 0.6% (0.6%) 0.42
Suprachoroidal hemorrhage 0 0.0% NA 0 0.0% NA NA
Endophthalmitis 0 0.0% NA 1 0.5% (0.5%) 0.54
Cystoid Macular Edema 1 1.9% (1.9%) 9 5.2% (1.7%) 0.29
Shallow Anterior Chamber 2 6.1% (4.2%) 2 1.5% (1.0%) 0.13
Hypotony maculopathy 1 0.5% (0.5%) 0 0.0% NA 0.54
Diplopia 4 6.1% (3.0%) 26 14.4% (2.6%) 0.085
Corneal edema, All 2 5.1% (3.6%) 27 17.8% (3.1%) 0.039
Tube-corneal touch 3 5.4% (3.0%) 5 3.0% (1.3%) 0.42
Corneal graft rejection 0 0.0% NA 9 5.4% (1.8%) 0.079
Band Keratopathy 1 1.4% (1.4%) 0 0.0% NA 0.10
Corneal neovascularization 0 0.0% NA 1 0.7% (0.7%) 0.59
Anterior Synechiae 0 0.0% NA 1 0.7% (0.7%) 0.59
Tube erosion 1 2.0% (1.9%) 2 1.2% (0.8%) 0.74
Encysted Bleb 0 0.0% NA 1 0.6% (0.6%) 0.56
Recurrent or persistent iritis 2 3.5% (2.4%) 9 5.2% (1.7%) 0.55
Phthisis bulbi 4 7.8% (3.8%) 1 0.5% (0.5%) 0.004
Hyphema 4 5.9% (2.9%) 0 0.0% NA 0.001
Vitreous hemorrhage 6 10.2% (4.0%) 0 0.0% NA <0.001
Pupillary membrane 1 1.6% (1.6%) 0 0.0% NA 0.089
Epiretinal membrane 1 1.4% (1.4%) 0 0.0% NA 0.10
Retinal Detachment 4 6.4% (3.1%) 0 0.0% NA 0.001
Corneal blood staining 2 2.8% (2.0%) 0 0.0% NA 0.020
Total Patients with Late Complications 34 53.0% (6.5%) 84 46.4% (3.8%) 0.57
†
In the one year follow-up report, the complications of 4 eyes occurring after complications explant of the study device were included in
percentages
*
Risk greater than 1.0 is associated with higher risk in NVG eyes, a risk less than 1.0 is associated with a higher risk in eyes with other diagnoses.
**
Cox proportional hazards model did not converge
‡
After publication of the one year report, the Data and Safety Monitoring Committee decided that one case of endophthalmitis was due to a corneal
transplant which occurred after implantation of the study shunt and that the necessity of performing the corneal transplant was due to pre-existing
corneal disease and not the study shunt
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Table 6





Reoperation for complications 12 (11%) 21 (20%)
Vision loss of ≥ 2 Snellen lines† 12 (11%) 17 (16%)
Total Patients with Serious Complications 24 (22%) 38 (36%)
Data are presented as number (percentage).
*
Total Numbers in this table are based on the number of participants who had a 36 month vision measured and/or had a previous complications
reoperation.
†
Some patients did not have Snellen Visual Acuity at 1 year because they missed the 1 year visit.
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